Roche's souped-up breast cancer drug steps on FDA fast track

Roche got the inside track in its final lap toward FDA approval for the armed antibody T-DM1. A new approach to treating HER2-positive breast cancer, the antibody-drug conjugate is seen as a significant advance for patients. The FDA put T-DM1 up for priority review, with a decision due by Feb. 26. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.